Oral fingolimod, a sphingosine-1-phosphate (S1P) receptor modulator, is an effective treatment for relapsing–remitting multiple sclerosis (MS), according to two double-blind, randomized controlled ...

Study investigators identified patients with MS who had initiated fingolimod therapy and were followed for 3 years post first therapy administration. Although other clinical trials have found reduced ...

Study Design The preliminary efficacy and safety of fingolimod was evaluated in a Phase II, 6-month, proof-of-concept study that randomized 281 patients to receive fingolimod 1.25 mg or 5.0 mg versus ...

September 22, 2010 — On September 22, the US Food and Drug Administration (FDA) announced approval of fingolimod (Gilenya, Novartis), the first of the long-anticipated oral treatments for multiple ...

A recent study sought to compare several available oral immunotherapies for the treatment of relapsing-remitting multiple sclerosis (MS). A recent study sought to compare several available oral ...

Please provide your email address to receive an email when new articles are posted on . Cycle Pharmaceuticals announced that the FDA has approved its Tascenso ODT, a bioequivalent to Gilenya, or ...

Tascenso ODT is a sphingosine 1-phosphate receptor modulator. Tascenso ODT ®, an orally disintegrating formulation of fingolimod, has been made available by Cycle Pharmaceuticals. The product is ...

The Appraisal Committee reviewed the data available on the clinical and cost effectiveness of fingolimod, having considered evidence on the nature of highly active relapsing–remitting multiple ...

Patients ages 50 or older with non-active multiple sclerosis (MS) who discontinued high-efficacy therapy (HET) had a higher risk of relapse compared with those who continued HET, a matched ...

In further draft guidance published today (1 December), NICE, the healthcare guidance body, has not been able to recommend a daily capsule that could reduce relapses in some people who have a ...